Sign in →

Test ID PBNP NT-Pro B-Type Natriuretic Peptide (BNP), Serum

Useful For

An aid in the diagnosis of congestive heart failure

Method Name

Electrochemiluminescence Immunoassay

Reporting Name

NT-Pro BNP, S

Specimen Type

Serum

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions:

1. Serum gel tubes should be centrifuged within 2 hours of collection.

2. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.

Additional Information: Patient's age and sex are required.

Forms: If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 365 days
  Refrigerated  7 days

Clinical Information

B-type natriuretic peptide (brain natriuretic peptide: BNP) is a small, ringed peptide secreted by the heart to regulate blood pressure and fluid balance.(1) This peptide is stored in and secreted predominantly from membrane granules in the heart ventricles in a pro form (proBNP). Once released from the heart in response to ventricle volume expansion and/or pressure overload, the N-terminal (NT) piece of 76 amino acids (NT-proBNP) is rapidly cleaved by the enzymes corin and/or furin to release the active 32 amino acid peptide (BNP).(2)

 

Both BNP and NT-proBNP are markers of atrial and ventricular distension due to increased intracardiac pressure. The New York Heart Association (NYHA) developed a 4-stage functional classification system for congestive heart failure (CHF) based on the severity of the symptoms. Studies have demonstrated that the measured concentrations of circulating BNP and/or NT-proBNP increase with the severity of CHF based on the NYHA classification.

Reference Values

Males

≤45 years: 10-51 pg/mL

46 years: 10-53 pg/mL

47 years: 10-55 pg/mL

48 years: 10-56 pg/mL

49 years: 10-58 pg/mL

50 years: 10-59 pg/mL

51 years: 10-61 pg/mL

52 years: 10-62 pg/mL

53 years: 10-64 pg/mL

54 years: 10-67 pg/mL

55 years: 10-68 pg/mL

56 years: 10-70 pg/mL

57 years: 10-71 pg/mL

58 years: 10-73 pg/mL

59 years: 10-76 pg/mL

60 years: 10-77 pg/mL

61 years: 10-79 pg/mL

62 years: 10-82 pg/mL

63 years: 10-83 pg/mL

64 years: 10-85 pg/mL

65 years: 10-88 pg/mL

66 years: 10-89 pg/mL

67 years: 10-92 pg/mL

68 years: 10-95 pg/mL

69 years: 10-97 pg/mL

70 years: 10-100 pg/mL

71 years: 10-103 pg/mL

72 years: 10-104 pg/mL

73 years: 10-107 pg/mL

74 years: 10-110 pg/mL

75 years: 10-113 pg/mL

76 years: 10-116 pg/mL

77 years: 10-119 pg/mL

78 years: 10-122 pg/mL

79 years: 10-125 pg/mL

80 years: 10-128 pg/mL

81 years: 10-131 pg/mL

82 years: 10-135 pg/mL

≥83 years: 10-138 pg/mL

 

Females

≤46 years: 10-140 pg/mL

47 years: 10-141 pg/mL

48 years: 10-144 pg/mL

49 years: 10-146 pg/mL

50 years: 10-149 pg/mL

51 years: 10-150 pg/mL

52 years: 10-152 pg/mL

53 years: 10-155 pg/mL

54 years: 10-157 pg/mL

55 years: 10-160 pg/mL

56 years: 10-162 pg/mL

57 years: 10-166 pg/mL

58 years: 10-168 pg/mL

59 years: 10-171 pg/mL

60 years: 10-173 pg/mL

61 years: 10-177 pg/mL

62 years: 10-179 pg/mL

63 years: 10-183 pg/mL

64 years: 10-185 pg/mL

65 years: 10-189 pg/mL

66 years: 10-193 pg/mL

67 years: 10-196 pg/mL

68 years: 10-199 pg/mL

69 years: 10-202 pg/mL

70 years: 10-206 pg/mL

71 years: 10-210 pg/mL

72 years: 10-214 pg/mL

73 years: 10-218 pg/mL

74 years: 10-222 pg/mL

75 years: 10-227 pg/mL

76 years: 10-230 pg/mL

77 years: 10-235 pg/mL

78 years: 10-239 pg/mL

79 years: 10-244 pg/mL

80 years: 10-248 pg/mL

81 years: 10-253 pg/mL

82 years: 10-258 pg/mL

≥83 years: 10-263 pg/mL

Cautions

Lack of N-terminal-pro brain natruretic peptid (NT-proBNP) elevations have been reported if congestive heart failure is very acute (first hour) or occurs with ventricular inflow obstruction (hypertrophic obstructive cardiomyopathy, mitral stenosis, atrial myxoma).

Day(s) Performed

Monday through Sunday; Continuously

Report Available

Same day/1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

83880

NY State Approved

Yes